Patients with congenital giant nevi (CGN), which can compromise quality of life and progress to melanoma, have limited treatment options. Choi et al. have demonstrated that topical application of a proinflammatory hapten for alopecia treatment [squaric acid dibutylester (SADBE)] caused nevus regression and prevented melanoma in an Nras mouse CGN model. Their results demonstrate the promise of repurposing drugs through precision modeling.
Keywords: M1 macrophages; Nras; congenital giant nevi (CGN); drug repurposing; genetically engineered mice (GEM); squaric acid dibutylester (SADBE).
Published by Elsevier Inc.